Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 December;62(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 December;62(4):349-68

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  MOLECULAR PET IMAGING IN ADAPTIVE RADIOTHERAPY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 December;62(4):349-68

DOI: 10.23736/S1824-4785.18.03087-X

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Biological PET-guided adaptive radiotherapy for dose escalation in head and neck cancer: a systematic review

Olga HAMMING-VRIEZE 1 , Arash NAVRAN 1, Abrahim AL-MAMGANI 1, Wouter V. VOGEL 1, 2

1 Department of Radiation Oncology, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, The Netherlands; 2 Department of Nuclear Medicine, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands



INTRODUCTION: In recent years, the possibility of adapting radiotherapy to changes in biological tissue parameters has emerged. It is hypothesized that early identification of radio-resistant parts of the tumor during treatment provides the possibility to adjust the radiotherapy plan to improve outcome. The aim of this systematic literature review was to evaluate the current state of the art of biological PET-guided adaptive radiotherapy, focusing on dose escalation to radio-resistant tumor.
EVIDENCE ACQUISITION: A structured literature search was done to select clinical trials including patients with head and neck cancer of the oral cavity, oropharynx, hypopharynx or larynx, with a PET performed during treatment used to develop biological adaptive radiotherapy by: 1) delineation of sub-volumes suitable for adaptive re-planning; 2) in-silico adaptive treatment planning; or 3) treatment of patients with PET based dose escalated adaptive radiotherapy.
EVIDENCE SYNTHESIS: Nineteen articles were selected, 12 articles analyzing molecular imaging signal during treatment and 7 articles focused on biological adaptive treatment planning, of which two were clinical trials. Studied biological pathways include metabolism (FDG), hypoxia (MISO, FAZA and HX4) and proliferation (FLT).
CONCLUSIONS: In the development of biological dose adaptation in radiotherapy for head-neck tumors, many aspects of the procedure remain ambiguous. Patient selection, tracer selection for detection of the radio-resistant sub-volumes, timing of adaptive radiotherapy, workflow and treatment planning aspects are discussed in a clinical context.


KEY WORDS: Head and neck neoplasms - Radiotherapy - Adaptive clinical trials as topic - Positron-emission tomography

top of page